SPOTLIGHT: Hollis-Eden skyrockets on preclinical cancer data
At the 2007 ASCO Breast Cancer Symposium, Hollis-Eden reported impressive data for HE3235, a preclinical candidate for breast cancer. HE3235 significantly inhibited the incidence of new tumors and stopped the growth of existing tumors in a preclinical model of breast cancer. The company's stock shot up 30 percent on the news. Last week, Hollis-Eden was featured in FierceBiotech's weekly series on emerging drug developers. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
